Johnson & Johnson (NYSE:JNJ) Shares Bought by Security National Bank


Share on StockTwits

Security National Bank boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 6.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,308 shares of the company’s stock after buying an additional 1,449 shares during the period. Security National Bank’s holdings in Johnson & Johnson were worth $4,159,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of JNJ. Cypress Point Wealth Management LLC purchased a new stake in Johnson & Johnson during the 4th quarter worth approximately $25,000. Iron Horse Wealth Management LLC purchased a new stake in Johnson & Johnson during the 4th quarter worth approximately $30,000. Joseph P. Lucia & Associates LLC purchased a new stake in Johnson & Johnson during the 4th quarter worth approximately $32,000. Klaas Financial Asset Advisors LLC purchased a new stake in Johnson & Johnson during the 4th quarter worth approximately $36,000. Finally, Interactive Financial Advisors purchased a new stake in Johnson & Johnson during the 4th quarter worth approximately $39,000. Institutional investors own 67.25% of the company’s stock.

Johnson & Johnson stock traded up $0.01 during mid-day trading on Thursday, hitting $163.62. The company’s stock had a trading volume of 70,805 shares, compared to its average volume of 8,177,090. The firm has a market capitalization of $430.76 billion, a PE ratio of 25.76, a price-to-earnings-growth ratio of 3.06 and a beta of 0.70. Johnson & Johnson has a 1 year low of $133.65 and a 1 year high of $173.65. The company has a current ratio of 1.48, a quick ratio of 1.24 and a debt-to-equity ratio of 0.51. The stock’s fifty day moving average is $161.06 and its two-hundred day moving average is $154.38.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Monday, January 25th. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.82 by $0.04. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The company had revenue of $22.50 million during the quarter, compared to analyst estimates of $21.62 billion. During the same period in the prior year, the business posted $1.88 earnings per share. The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year. On average, equities analysts expect that Johnson & Johnson will post 7.99 EPS for the current fiscal year.

JNJ has been the subject of several research reports. Cantor Fitzgerald boosted their price objective on Johnson & Johnson from $180.00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 26th. Cowen upped their price target on Johnson & Johnson from $170.00 to $195.00 and gave the company an “outperform” rating in a research report on Wednesday, January 27th. Wells Fargo & Company upped their price target on Johnson & Johnson from $175.00 to $190.00 and gave the company an “overweight” rating in a research report on Wednesday, January 27th. Credit Suisse Group upped their price target on Johnson & Johnson from $168.00 to $193.00 and gave the company an “outperform” rating in a research report on Wednesday, January 27th. Finally, Raymond James upped their price target on Johnson & Johnson from $158.00 to $183.00 and gave the company an “outperform” rating in a research report on Wednesday, January 27th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $178.60.

About Johnson & Johnson

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also: How Buying a Call Option Works

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.